GIVE Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the Genetic Medicines and Individualized Manufacturing (GIVE) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here or the accuracies of the statements made therein. Submissions to the teaming profiles list are reviewed and updated periodically.
GIVE Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Xuan Wang | Virginia Tech | xuanw@vt.edu | Blacksburg, VA | We have a recent pitch video on “Towards Intelligent and Resilient U.S. Pharmaceutical Supply Chains via Multi-Agent AI” has been deemed Awardable by the DARPA ERIS Marketplace. | Manufacturing partners | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Karen Weisinger | Cell X Technologies | kweisinger@cellxtechnologies.com | WOBURN, MA | Cell X brings a fully, automated solution for adherent cell manufacturing, anchored by it's proprietary Celligent system and C-Suite software platform, together enabling low variability and data-rich workflows that enable IND submissions. Using the Celligent, we have a strong track record of generating iPSC cell lines as well as various types of target cells from iPSCs in both research and GMP settings, making our platform especially suitable for the automation portion of the GIVE initiative. | We seek a therapeutic developer partner for the GIVE initiative to automate processes on our system and create reliable therapeutics. Our goal is to collaborate on an innovative therapy that truly benefits from automation, where the synergy of our technologies and expertise is greater than the sum of its parts. | TA2: Integrated Quality Control |
| Graham Taylor | Helix Biotech, Inc. | graham@helix-biotech.com | Knoxville, TN | Helix Biotech specializes in custom DNA/RNA synthesis and the development and GMP manufacturing of nucleic acids, lipid nanoparticles (LNPs), liposomes, and hybrid nanoparticles. | Open to teaming for any needs | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| John Cooke | Houston Methodist Research Institute | jpcooke@houstonmethodist.org | Houston, TX | Our Center for RNA Therapeutics generates fundamental insights in RNA Biology, translating them into transformative therapies for patients. We have novel platforms for circular RNA and more stable mRNA structures with high translational efficiency; and generate AI algorithms for computational RNA biology and therapeutics. Our RNACore synthesizes, purifies, encapsulates, and validates clinical grade mmRNA and circular RNA in ISO7 clean rooms with a cGMP trained team for FDA-approved INDs. | To our knowledge, we are the only AMC capable of generating mmRNA and circular RNA drugs for clinical trials; and have great expertise in synthesis, purification, encapsulation and QC (having made about 600 constructs for about 175 clients; primarily research grade). We are looking for scientists that have expertise in mmRNA-based gene therapy; as well as a medtech company that intends to develop a deployable manufacturing unit for hospital-based personalized mRNA (or circRNA) therapies | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Melik Demirel | Penn State University | melikdemirel@gmail.com | university park, PA | high-throughput assays for RNA biomanufacturing | companies or institutes with next generation therapies expertise | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Ganeshkumar Varadarajalu | Molariti, Inc. | ganesh@molariti.com | Cambridge, MA | At Molariti, we are developing a patent-pending semiconductor biosensor chip that can detect biomolecules with single molecule sensitivity, rapidly, and accurately at a low cost. With integrated fluidics, it offers a simplified and a fully automated workflow to analyze biomolecules. With support from NIGMS/NIH we are developing a scalable version of the chip that can be applied for high-throughput integrated quality control of genetic medicines. | We are seeking collaborators to integrate our semiconductor biosensor chip into genetic medicine manufacturing for integrated quality control. Ideal partners operate automated RNA production on GMP-compliant lines, provide LIMS or edge analytics, and help develop and validate mRNA CQA assays, manage reference standards, and host pilot sites. We also welcome manufacturing and microfluidics partners for scale up and validation across multiple sites. | TA2: Integrated Quality Control |
| Mary Napier | p-Chip | pcc-partnerships@p-chip.com | Chicago, IL | Integrated QC: Using handheld p-Chip readers and Authium digital identity software platform to create crypto-anchors secured by blockchain. A system that links physical biomanufacturing components to a trusted digital identity. R&D: 1) Supply chain integrity via blockchain IDs to cut scrap; 2) Digital COI/COC for assets; 3) Serialized genealogy for single-use components; 4) Extreme condition and tamper-proof tests; 5) Seeking use case dev in RNA manufacturing. | We’re a Chicago-based company with a novel micro-chip transponder the size of a grain of salt—the p-Chip. We are seeking ARPA-H GIVE partners in our 5 R&D areas across life-science consumables, biomanufacturing, and diagnostics. Central to our platform are light-activated p-Chips that emit unique IDs for traceability and authentication—indelible, scalable, blockchain-ready, and extreme condition resilient. Together we can demonstrate zero-error process control. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Chelsea Trengrove | Neoclease | chelsea@neoclease.com | Boston, MA | Neo is pioneering AI-driven, gene-specific nucleases and mini prime editors that overcome the targeting, size, and off-target hurdles of Cas9. Our compact (<650 aa), PAM-independent editors enable tunable, single-gene precision editing in vivo. Using an AI-guided in silico design cycle that completes in one week and in vitro validation in six, we rapidly generate and optimize bespoke editors to advance curative programs for rare diseases. | We'd like to be brought on as the proof point for this initiative, with our gene-specific editors. | TA1: Automated RNA Manufacturing |
| Hall Johnson | MassMatrix Inc. | hjohnson@massmatrix.bio | Columbus, OH | Best-of-breed mass spectrometry data analysis software solution for RNA with automated and high-throughput workflows for sequencing, intact mass deconvolution and XIC quantitation. The molecule agnostic architecture enables a unified solution for nucleic acids, proteins, lipids and more. Software is API-centric and natively built for the cloud. www.massmatrix.bio | We are interested in being a subcontractor so we seek a prime contractor in need of expertise and existing software capabilities in mass spectrometry data analysis. | TA2: Integrated Quality Control |
| Molly McGlaughlin | Revolution Biomanufacturing Inc. | molly.mcglaughlin@revolutionbiomanufacturing.com | Worcester, MA | US, Woman, Disabled Veteran owned small business with solid intellectual property and capabilities for continuous manufacturing of Nucleic based therapeutic drugs from pDNA, mRNA, saRNA, CircRNA, LNPs, Lyophilization formulas, and support services. The personalized medicine model has returned a patient's individual therapy from a tumor sample in 6 weeks and is getting faster. | We can provide expertise in the manufacturing of nucleic acids products Cell freed DNA templates, pDNA, mRNA, saRNA, CircRNA, LNP and the analytics to support personalized medicines (neoantigen, CA-T, CAS9, and other gene editing) | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Ben Lerman | DINYA | ben@dinyadna.com | Oakland, CA | DINYA's novel enzymatic DNA synthesis process achieves industry leading quality and speed for IVT RNA applications. | We seek partnership expertise downstream of DNA template creation, including: IVT, encapsulation, fill finish, and QC for GMP processes. | TA1: Automated RNA Manufacturing |
| Wayne Doyle | Eclipsebio | wayne.doyle@eclipsebio.com | San Diego, CA | Eclipsebio develops sequencing-based analytics to validate and optimize RNA therapeutic design and manufacturing. Our platforms integrate predictive AI with next-generation sequencing assays to deliver high-resolution quality control and characterization data. By replacing outdated methods with data-driven insights, we enable developers to design, validate, and scale RNA medicines with greater precision, reliability, and speed. | Eclipsebio seeks partners who share our vision of accelerating RNA medicine through integrated innovation. We provide AI-driven design and sequencing-based validation to ensure therapies are both optimized and rigorously characterized. We offer teammates robust analytics to confirm that biomanufacturing processes are reliable and provide actionable data to improve quality, efficiency, and reproducibility. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Eeshit Dhaval Vaishnav | Sequome | edv@sequome.com | South San Francisco, CA | Sequome designs biological sequences building on Gene Genie, our AI platform published on the cover of Nature. | Microfluidics and Automation Specialists, Analytical and QC Technology Providers, Bioprocess and Device Companies, Academic/Clinical Partners for Pilots | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Pooja Tiwari | ARNAV Biotech | pooja.tiwari@arnavbiotech.com | Atlanta, GA | RUO RNA manufacturing for vaccines, therapeutics, genetic medicines and pre-clinical testing | We can support prime organizations by offering RNA manufacturing support, formulation and testing | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Krishanu Saha | University of Wisconsin-Madison | ksaha@wisc.edu | Madison, WI | Developing and clinically implementing innovative RNA-based CRISPR therapies, cancer vaccines, and RNA-modified cell therapies for rare pediatric and adult diseases. | UW-Madison is open to all suggestions for collaboration in this area. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Freddy Nguyen | Nine Diagnostics | freddy.nguyen@ninediagnostics.xyz | Cambridge, MA | Nine Diagnostics develops an AI-enabled nanosensor platform for real-time, in-process quality control in genetic medicine and cell therapy manufacturing. Our carbon-nanotube optical sensors provide rapid, multiplexed proteomic and metabolomic readouts from microliter samples, enabling continuous monitoring of product consistency, cell health, and process stability across distributed biomanufacturing workflows. | We seek partners developing RNA, cell, or gene therapy manufacturing systems who need integrated, automated quality control. Ideal collaborators include bioreactor, process, or analytical platform developers interested in embedding real-time nanosensor feedback to reduce batch variability, accelerate release testing, and enable distributed or on-demand manufacturing. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Minghong Zhong | GeneLancet Biosciences, INC | MINGHONG.ZHONG@genelancetbio.com | Doylestown, PA | GeneLancet (www.genelancetbio.com) advances precision gene editing with its proprietary LgRNA technology. LgRNAs outperform classical guides like sgRNAs and pegRNAs in key areas: superior product quality for enhanced safety, optimized drug-like properties for better delivery, and unmatched scalability for efficient manufacturing. | We seek collaborations in all CRISPR platforms. Check out our guide RNA white paper (https://www.genelancetbio.com/genelancet-guide-rna-white-paper). | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Aaron Leopold | NTxBio | aaron.leopold@ntxbio.com | Rio Rancho, NM | NTxBio has an automated and fully-closed benchtop system for continuous flow RNA synthesis and purification. The system produces high-integrity, high-purity mRNA or saRNA up to 11.5+kb and is designed for personalized medicine with instant changeover between constructs. | We seek therapeutic partners as well as upstream DNA synthesis and downstream encapsulation partners to create an integrated end-to-end manufacturing system. | TA1: Automated RNA Manufacturing |
| Marc Taraban | University of Maryland Baltimore | mtaraban@rx.umaryland.edu | Rockville, MD | PAT for noninvasive final product inspection and in-line process monitoring for cell and gene therapy products. Examples include assessing empty/full ratio for viral vector products in gene therapy and cell count and viability in cell therapy. The technology, wNMR, involves no sample preparation and no reagents (e.g., https://pubs.acs.org/doi/10.1021/acs.analchem.1c04088) | Manufacturers of cell and gene therapy products. | TA2: Integrated Quality Control |
| Roger Tang | Triple Ring Technologies | rtang@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products across medtech and life sciences. Our interdisciplinary team, including many PhDs, excels in advancing technologies to FDA approval while collaborating with academic researchers. We are currently engaged with ARPA-H on a number of programs. We offer services for development of devices and systems and have direct experience in cell & gene therapy and related quality control diagnostics. We are ISO 13485 certified. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We are looking for teaming partners that could use our collaborative assistance to design enabling devices and technologies while navigating the FDA regulatory pathway. We have acted as prime, subcontractor, or vendor on previous submissions. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Mike Valliere | Ribbon Bio | Michael.Valliere@ribbonbiolabs.com | Philadelphia, PA | Ribbon bio is focused on fully automating cell free DNA manufacturing. | We are looking for expertise in QC and CMC for RNA manufacturing. | TA1: Automated RNA Manufacturing |
| Matthew Taylor | University of Colorado Anschutz Medical Campus | matthew.taylor@cuanschutz.edu | Denver, Colorado, CO | Human genetic cardiomyopathies, predominantly dilated and arrhythmogenic; lysosomal storage diseases; rare adult genetic disorders | Our expertise is more on the clinical/translational side; we identify mutation(s) in patients, families, cohorts; we are looking for partners to translate those mutations into targets for rapid therapy development | TA1: Automated RNA Manufacturing |
| Anna Blakney | University of British Columbia | anna.blakney@msl.ubc.ca | Vancouver, BC | We specialize in designing RNA and optimizing manufacturing for large RNA modalities, and have capacity for QC of RNA using sequencing and ddPCR. | Complementary expertise for automated manufacturing and integration of QC. | TA1: Automated RNA Manufacturing |
| Denise Pinson | Medvacon Life Sciences LLC | denise.pinson@medvacon.com | Sparta, NJ | Medvacon is a life sciences consulting firm specializing in quality systems, compliance, and cGMP readiness for regulated environments. Our work centers on designing and implementing quality management systems, leading technology transfers, and ensuring inspection readiness through robust validation and audit processes. We provide deep expertise in laboratory systems, including method validation, instrument qualification, CSV, regulatory documentation, training and remediation support. | Within a teaming relationship, Medvacon would serve as the compliance and quality oversight partner, leading efforts in validation, QA integration, risk management, and regulatory readiness. We would ensure that analytical methods, automated systems, and digital platforms meet FDA, ICH, and GMP standards, helping translate technical innovations into reliable, audit-ready, and scalable QC frameworks aligned with the goals of the GIVE TA2 initiative. | TA2: Integrated Quality Control |
| Balaji Sitharaman | Millennial Scientific | balaji@millennialscientific.com | Stony Brook, NY | We are developing 3D-printed stationary phase materials for the integrated extraction and pre-fractionation of target RNA from other biomacromolecules, followed by separation for downstream quality testing or purification for production. This technology aims to be suitable for distributed manufacturing, economical, and efficient, while minimizing reagent use and footprint. It will also integrate with upstream lysate preparation and downstream sensors for further quality testing or purification. | - We are seeking potential partners who are developing Cell-free RNA manufacturing platforms that require downstream integrated extraction and separation of RNA, either for quality analysis or scale-up purification. -We are also seeking partners that develop or provide bioprocess extraction and separation instrumentation, including pumps for fluid flow, and analytical detectors. | TA2: Integrated Quality Control |
| Michael Patrick | Phizzle Inc | mpatrick@phizzle.com | San Francisco, CA | Using custom hardware and software Phizzle's solution enables regulated manufacturers to connect, automate and integrate analytical instruments and scientific workflows directly with Digital Systems — eliminating pen and paper methods, multistep data entry SOPs and clunky middleware solutions. | Partners whose processes would benefit from seamless integration into control and monitoring systems. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Brent Dixon | BioCytics, Inc | bdixon@biocytics.com | Huntersville, NC | BioCytics, Inc.’s mission is to provide patients with affordable individualized precision medicine options through clinical trials. As the only independent, privately held, Point of Care (PoC) personalized and individualized cell and gene therapy manufacturing facility in the US co-located with Carolina BioOncology Institute, PLLC (CBOI) Phase 1 Clinical Trials research center. We are able to leverage our infrastructure for innovative biomanufacturing of RNA-based genetic medicines together. | Medical device manufacturers and engineers to leverage our expertise in molecular biology for cell and gene therapy with proprietary Warm-Chain PoC Manufacturing. Analytical device manufacturers to leverage our diagnostic assay expertise. BioCytics-CBOI infrastructure forms a fully integrated platform for decentralized manufacturing of personalized and individualized gene therapy in the onsite GMP compliant Human Applications Lab (HAL). | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Shai Zilberzwige Tal | The Weizmann Institute | shai.zil22@gmail.com | The Weizmann Institute, Rehovot, Israel | Our lab develops microfluidic platforms for cell-free RNA synthesis, purification, and lipid nanoparticle (LNP) encapsulation within a single enclosed device. The system enables efficient production of mRNA-LNPs therapeutics. We aim to advance this platform toward automated and GMP-adaptable workflows for distributed, on-demand RNA manufacturing and personalized medicine applications. | We are seeking collaborators with expertise in enzymatic DNA synthesis, automation engineering, and quality control (QC) to complement our microfluidic RNA-LNP platform. Ideal partners would contribute to developing upstream DNA template generation, automating system operation for GMP compatibility, and integrating analytical or sequencing-based QC modules to enable reliable, distributed RNA manufacturing. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Roberta Duncan | Arcturus Therapeutics | roberta.duncan@arcturusrx.com | San Diego, CA | Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. | Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. | TA1: Automated RNA Manufacturing |
| Eric Van Gieson | EQUALA | Evangieson@epochepigenetics.com | Baltimore, MD | Protein and RNA manufacture, derived from multiple DARPA programs | Seeking partners who have experience in RNA mnufacturing | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Jessica Bishop | Ceria Therapeutics | jessica.bishop@ceriatx.com | San Juan, PR | Ceria manufactures small batch bespoke synthetic novel RNA. The company's focus includes RNA modulation of inflammatory pathways, nanoparticle formulation science, and translational research integrating RNA design, proprietary nanoparticle delivery, and in-house manufacturing. | Seek collaboration partners with expertise in synthetic RNA design and synthetic RNA analog manufacturing/synthesis. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Baley Reeves | The National Center for Therapeutics Manufacturing | baley@tamu.edu | College Station, TX | The National Center for Therapeutics Manufacturing (NCTM) is a contract research organization that supports process development and scale up for therapeutic modalities. We have mRNA capabilities up to 5g/day scale with the automated Quantoom Midi system onsite, as well as platformsprocesses for pDNA production, mRNA manufacturing from 1mg-5g scale, and LNP formulation. | QC Assay development, Quality Systems, Regulatory Affairs | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Mike Hourigan | International Academy of Automation Engineering | mhourigan@myiaae.org | Conshohocken, PA | We are a Not For Profit Education and Credentialing organisation with our focus and expertise in Life sciences. We have a strong background in Research projects which can be reviewed at our Knowledge Center (www.myiaae.org/knowledge-center). We have deep expertise in applied technologies for life Science manufacturing and we develop our work product in conjunction with our Life Science Advisory Board (www.myiaae.org/life-science-advisory-board/) | We will be seeking partners in different geographic regions in the US along with scientific research support in the area's under study. We will look to collaborate with current biotech manufacturing companies and process equipment vendors. Additionally technology (software and hardware) providers. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Mary Allen | University of Colorado Boulder | mary.a.allen@colorado.edu | Boulder, CO | We have discovered that each gene and metabolite has an acceptable RNA and metabolic range in humans. When the expression is too high or too low, disease can result. Our goal is to work with GIVE teams to ensure patients receiving individualized ASO therapies remain within these ranges through real-time RNA monitoring and reversible control of treatment effects. | Our work shows that precisely adjusting RNA levels—up or down—can treat many diseases, but the safe range is person-specific. We seek partners developing therapies that tune RNA abundance and share our interest in creating paired antisense oligos with antidotes, where one ASO can reverse or stop the action of another ASO if expression changes too far. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Randy Dyer | Elegen | randy.dyer@elegenbio.com | Menlo Park, CA | Elegen brings unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. Elegen uses proprietary cell-free technologies to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com and connect with us on LinkedIn and X. | To our knowledge we are the only DNA manufacturers with a scalable, capital-efficient, fully automated cell-free DNA production platform poised for rapid deployment. We welcome the opportunity to partner with integrators, RNA manufacturers, software and reagent developers in this endeavour. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Paul OSullivan | Skellig | paul.osullivan@skellig.com | Center Valley, PA | Skellig Manufacturing develops the Internet of Medicine (IoM) — a digital operating system for biomanufacturing that connects process equipment, analytics, and regulatory oversight into one real-time network. Our current focus is automating RNA manufacturing and inline quality verification through IoM-enabled skids that allow therapies to be made locally and validated globally. | Skellig seeks partners with expertise in automated RNA process hardware, single-use flow paths, and inline analytical modules to co-develop a point-of-care manufacturing system under GIVE. We are teamed with Verdot Biotechnologies for skid design and fabrication and welcome collaborators in QC analytics, formulation, and regulatory systems integration. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Arye Lipman | Biosphere | arye@biosphere.io | Oakland, CA | Biosphere has developed UV sterilized biomanufacturing systems for production of a wide array of biotech products. These highly automated, modular units have operational advantages over single-use / steam sterilized, and may be field deployed for use at point of need. We have a team of engineers and scientists developing biomanufacturing infrastructure both upstream and downstream to address urgent natsec needs. | Biosphere's bioreactor platform is flexible and process agnostic - we are looking for partners with a particular bioproduct of interest who would like to manufacture using our systems (or co-develop new systems) to address the needs of ARPA-H or other federal agencies. | TA1: Automated RNA Manufacturing |
| Guillaume Roelandts | Quantoom Biosciences | g.roelandts@quantoom.com | 11 Rue de la Maitrise, 1400 Nivelles, Walloon Brabant, Belgium | Quantoom Biosciences develops the N-FORCE toolbox to enable streamlined m(sa)RNA drug development. This includes Ncode for template design, Ntensify® for RNA synthesis, and Ncapsulate® for delivery. Our integrated, modular platform supports applications from early research to GMP manufacturing, addressing both therapeutic and vaccine needs | Quantoom seeks partners with complementary capabilities in synthetic DNA (e.g., enzymatic synthesis, DNA circularization,...) and advanced Process Analytical Technologies (PAT) to enhance quality control, automation, and real-time monitoring of RNA production. Expertise in AI-driven optimization, microfluidics, or inline analytics would further strengthen the collaboration | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Arezoo Ardekani | Purdue University | ardekani@purdue.edu | West Lafayette, IN | We research the manufacturing of lipid nanoparticles and their characterization. We study the role of turbulence and mixing on nanoparticle assembly and scale-up manufacturing (npj Drug Discov 2025). We have developed emerging methods such as machine learning based hyperspectral imaging for label-free, high-throughput classification of LNPs (Int Pharm 2025:126065) and machine-learning frameworks trained on large LNP datasets to predict activity (ACS Appl Bio Mater 2025:3717). | We are looking for additional expertise in the area of integrated quality control and automated RNA manufacturing. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Jonathan (Jack) Reid | Unicorn Biotechnologies | jack.reid@unicornb.io | Newark, NJ | We build modular, autonomous, machine-intelligence enabled biomanufacturing systems, develop novel PAT and detection systems, and design, manufacture and deliver operatorless ‘self-driving’ bioproduction systems with integrated production/analytical workflows that can be field-deployed in non-centralized, non-cleanroom production environments. All engineering (hard/software, data ifra, ML/AI development, API/systems integration, eQMS/ELN recording) and biotesting is preformed in-house. | We are looking to partner with groups 1) focusing on RNA design and biology (e.g. enabling technology or therapeutic developers) across the RNA types (mRNA, saRNA, transRNA, circRNA) and product categories (P/I cancer, neoantigen therapy, gene/base/prime editing. 2) RNA-based cell therapy developers (e.g. RNA-CAR, T-cell engager, RNA mediated iPSC reprogramming, etc.). 3) delivery systems (e.g. LNP). | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Simha Sethumadhavan | Columbia University | simha+arpahgive@columbia.edu | New York City, NY | My lab specializes in secure by design, "zero trust" security and privacy architecture, implementation, testing and monitoring. | n/a | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Sixuan Li | CICS Analytics Corp. | cicsanalyticsinc@gmail.com | Baltimore, MD | We develop advanced automated single-molecule detection platforms for RNA therapeutic quality control. Our technology quantifies multiple quality attributes at single-particle resolution, invisible to conventional methods, including empty particle fraction, drug payload quantity and distribution, and other properties, including particle size and encapsulation efficiency. With superior sensitivity and high-throughput, we reveal critical attributes that directly impact drug efficacy and safety. | As a TA2 solution, we seek partners and collaborators requiring integrated quality control solutions, including: Biopharma with RNA therapeutic pipelines needing advanced analytics, CRO/CDMOs pursuing distributed manufacturing capabilities equipment manufacturers developing GMP-compliant systems, software developers for 21 CFR Part 11 compliance, and pharmaceutical quality systems integration. We are particularly interested in teams targeting multi-site, multi-product manufacturing networks. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Jesse Dill | Ginkgo Bioworks | jdill@ginkgobioworks.com | Boston, MA | We have a team focused on RNA design including particular expertise in circRNA and mRNA designs, as well as expertise in polymerase engineering for improved nucleic acid productivity and purity, as well as other nucleic acid-modifying enzymes. | We are looking for partners with expertise in device engineering. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Rich Stoner | Exthymic Corporation | rich.stoner@exthymic.com | San Diego, CA | Exthymic develops technologies for point-of-care manufacturing of personalized cell therapies, integrating advanced cell processing, RNA delivery, in-line characterization, and novel assays for deep cell insight. Our engineering-driven, cross-functional team has in-house fabrication capabilities and a strong understanding of regulatory and economic factors critical to deploying technologies at the point of care. | We seek collaborators with technologies to integrate into our point-of-care cell engineering platform to meet the high standards of the GIVE solicitation. Ideal partners offer rapid enzymatic RNA/DNA synthesis, automation-ready assay technologies compatible with microfluidics, or RNA-based cell therapy assets aligned with GIVE objectives. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Nathan Stover | BioCurie | nathan@biocurie.com | Newark, DE | BioCurie is a startup focusing on developing digital tools to aid in biopharmaceutical process development. Owing to the previous experience of BioCurie’s team members in RNA manufacturing, BioCurie is uniquely positioned to contribute to the GIVE project as a team member providing digital tools for process modeling and process control. These tools are de-risked based on previous academic work and will be broadly impactful across the timeline of process development. | As BioCurie is a software company, it is best suited to be a partner as a part of a larger team which includes experimental and equipment manufacturing teams. | TA1: Automated RNA Manufacturing |
| jesse erasmus | HDT Bio | jesse.erasmus@HDT.BIO | Seattle, WA | We develop next-generation RNA therapeutics enabled by a proprietary, clinically validated delivery formulation proven safe in over 6,000 humans. Our research spans in vivo and ex vivo RNA delivery (mRNA, saRNA, transRNA), rapid on-demand manufacturing, and integrated analytical and automation technologies to support distributed, patient-tailored RNA therapy production. | We seek partners offering automated RNA or DNA manufacturing platforms, process analytics, digital-twin QC, and GMP implementation expertise. Ideal collaborators can complement our delivery technology with capabilities in continuous manufacturing, inline quality monitoring, or regulatory/CMC development to advance end-to-end, point-of-care RNA manufacturing solutions. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Blerina Shkodra | Leon-nanodrugs GmbH | b.shkodra@leon-nanodrugs.com | Munich, Bavaria, Germany | LEON has developed the NANOme® system for GMP-compliant manufacturing for the nanoencapsulation of RNA and other nucleic acids. Equipped with 21 CFR Part 11–compliant software and LEON’s proprietary FR-JET® modular mixer, NANOme enables rapid, back-to-back aseptic production of up to 140 batches in Grade C environments at decentralized, point-of-care sites, democratizing access to advanced therapeutics globally. | LEON seeks partners for synthetic DNA and automated IVT mRNA production and downstream partners for single-use tangential flow filtration, Fill & Finish, and biotech LNP drug developers. Together, these collaborations would enable rapid, scalable, and decentralized RNA-LNP manufacturing, accelerating global access to advanced therapeutics. | TA1: Automated RNA Manufacturing, TA1: Automated RNA Manufacturing |
| Sunandan Saha | Sartorius NA | sunandan.saha@sartorius.com | Marlborough, MA | Sartorius is a leading innovator in the life sciences and pharmaceutical manufacturing industry. Sartorius is developing solutions for manufacturing RNA based therapies in a robust, scalable and cost-efficient manner. These solutions will provide distributed and sclable manufacturing solutions for RNA based therapy manufacturing | We are looking for partners who can collaborate with us to implement our solutions in a real-world situation. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Maksym Krutko | imec USA | max.krutko@imec-int.com | Cambridge, MA | Imec applies semiconductor expertise to develop chip-based platforms for high-throughput DNA/RNA synthesis, on-chip PCR, and advanced fluidics for parallel genetic screening. Integrated optical, electrochemical, and impedance sensors enable real-time bioreactor monitoring, delivering scalable, automated, and data-rich biomanufacturing solutions. (TA1 & TA2 capabilities) | Imec seeks partners in both TA1 and TA2 to integrate chip-based synthesis, sensing, and process-control technologies into distributed and automated biomanufacturing systems, accelerating scalable, high-fidelity genetic and cellular production. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Donghoon Lee | Omphalos Lifesciences | donghoon.lee@omphaloslifesci.com | Dallas, TX | Omphalos Lifesciences develops advanced computational modeling technology for scalable, high-fidelity simulations of biological and experimental systems. For the GIVE program, we model RNA synthesis and encapsulation workflows to capture reaction kinetics, resource use, and variability. Our AI layer refines parameters and QC thresholds, translating simulated performance into executable settings to contribute to a full digital twin experience across distributed sites. | Omphalos Lifesciences seeks partners developing cell-free RNA synthesis, formulation, or QC systems that require simulation, optimization, and AI-based control integration. Our digital twin models predict manufacturing outcomes, optimize parameters, and validate QC performance in real time. We aim to integrate our simulation engine into GIVE systems to enable predictive process control, distributed validation, and measurable efficiency and quality improvements. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Jiangsheng Xu | General Therapeutics | jxu@generaltx.com | Gaithersburg, MD | General Therapeutics offers highly effective, non-reactogenic proprietary iLDC platform LNPs that achieve up to 10x higher mRNA expression and 70% less inflammation than current commercial formulations. Through our QuikLNP™ Formulation technology, we are pioneering decentralized, cold-chain-free mRNA manufacturing, enabling on-site and on-demand vaccine and therapeutic production. | We have developed superior ionizable lipids, optimized LNP formulations, and a portable LNP manufacturing platform. We are seeking partners with expertise in device or hardware engineering and decentralized RNA manufacturing solutions to co-develop integrated, on-site production systems for next-generation RNA medicines. | TA1: Automated RNA Manufacturing |
| Patrick Thiaville | 4basebio | patrick.thiaville@4basebio.com | Cambridge, UK | 4basebio is a biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces RUO, High Quality, and GMP-grade synthetic DNA with speed, purity, and scalability, overcoming the limitations of plasmid-based systems. | The company is looking to partner with teams working on gene therapies, genome editing, mRNA production and DNA vaccines. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Curt Hewitt | Signature Science, LLC | chewitt@signaturescience.com | Austin, TX | Signature Science’s proprietary PiplineTM microfluidic technology has broad applicability to the automation of molecular processes that can be performed at different scales using stabilized reagents compatible with low resource environments. Separately, our SEQ-OUT TM system uses this technology to automate rapid RNA sample preparation, sequencing library preparation, and MinION sequencing with direct applications for the comprehensive quality control of RNA therapeutics. | We seek partners with experience in the production of RNA therapeutics who are interested in automating their manufacturing processes. We also seek partners in need of an automated next generation sequencing-based quality control system as part of their proposed solution for this program. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Rajeev Kumar | AutoFrax LLC | autofrax@gmail.com | Duluth, GA | AutoFrax LLC develops modular Delta-robotic platforms that integrate automated biomanufacturing, precision microfluidics, and real-time functional quality control (QC). Building on Dr. Rajeev Kumar’s pioneering high-throughput RNAi microarray research in mammalian systems (Genome Research, 2003), AutoFrax is advancing automated RNA synthesis, purification, potency assessment, and off-targeting analysis to enable distributed, scalable, and high-quality RNA therapeutics manufacturing. | Seeking collaborators in RNA synthesis chemistry, GMP process validation, and mammalian-cell functional assay miniaturization to co-develop a distributed, end-to-end RNA manufacturing and integrated QC system under ARPA-H GIVE Technical Areas 1 and 2 (Automated RNA Manufacturing and Integrated Quality Control). | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Inna Shcherbakova | Waterfall Scientific | inna.shcherbakova@waterfallsci.com | Worcester, MA, MA | Waterfall Scientific aims to revolutionize mRNA medicine manufacturing using patented DuoTetherTM technology to enable bench top, fluidics-based, GMP certified drug product production. | Seeking collaborators with technical expertise in regulatory, on-chip DNA production & fill-finish | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Thomas YBERT | DNA Script | ty@dnascript.co | San Francisco, CA and Paris, France, CA | DNA Script develops enzymatic DNA synthesis (EDS) technology enabling fast, decentralized DNA production. Our upcoming Biofoundry platform converts digital sequences into ready-to-use gene DNA in days, directly on site. It provides scalable, automated, and high-fidelity gene synthesis for mRNA, cell and gene therapy, and personalized medicine applications — accelerating innovation in biomanufacturing and distributed therapeutic development. | We seek partners with drug development and clinical programs to integrate our Biofoundry technology, as well as regulatory, CMC, and FDA experts to guide DNA manufacturing compliance. We also aim to team with leaders in mRNA, cell and gene therapies, and personalized medicine to demonstrate the platform’s impact on accelerating and decentralizing therapeutic development | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Timothy Mercer | The University Of Queensland | t.mercer@uq.edu.au | St Lucia, Brisbane, Australia 4067 | The BASE mRNA Facility at The University of Queensland is a leading Australian centre for mRNA science and manufacture. We have end-to-end capabilities in the design, manufacture, and formulation of mRNA medicines, with experience building mRNA medicines for diverse clinical applications. Our research expertise includes computational sequence design, isothermal enzymatic mRNA synthesis, nanopore sequencing quality control and analysis and targeted mRNA-LNP delivery. | We are seeking partners that complement our strengths in mRNA design, rapid enzymatic mRNA production and real-time Nanopore quality control and analysis. This includes US-based partners with near-clinic or hospital biomanufacturing capabilities for mRNA or gene therapies, and experience in GMP operations and regulatory compliance. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Vivian Cheung | Brown University | vivian_cheung@brown.edu | Providence, RI | I am the Founding President of the Human RNome Project Consortium, which is sequencing full-length human RNA with all its chemical modifications. We are building a set of modifications—the full spectrum of modified RNAs—as calibration standards for direct RNA sequencing. This will enable AI-driven prediction of RNA function, precision manufacture of RNA medicines, and quality control in distributed biomanufacturing. | We seek partners developing scalable RNA manufacturing, formulation, and delivery systems to integrate with our sequencing and standards platform. Our team is building direct RNA sequencing and chemically modified RNA for real-time quality control and traceability, enabling robust, distributed biomanufacturing of RNA-based therapeutics. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Asmay Gharia | Rivulet Inc. | asmay@rivulet.bio | New York, NY | Rivulet develops real-time, inline process analytical platforms for advanced biologics and RNA manufacturing. Our core research is in Dielectrophoresis-Guided Impedance Spectroscopy (DIG-IS) which combines dielectrophoretic positioning, broadband impedance sensing on polymer electrodes, and machine-learning control algorithms. We manufacture hardware for continuous, label-free monitoring of process status and product quality within compact, automated units. | Potential teaming partners include (1) GMP-experienced RNA manufacturers capable of producing and purifying multiple RNA modalities; (2) formulation and encapsulation specialists developing lipid or polymeric delivery systems for RNA; (3) quality-systems and regulatory experts experienced with eQMS/LIMS implementation; and (4) academic or translational centers able to serve as distributed manufacturing test beds for hardware integration and verification. | TA2: Integrated Quality Control |
| Ian Bellayr | Diakonos Oncology | i.bellayr@diakonosoncology.com | Houston, TX | Diakonos Oncology Corporation is a clinical stage biotech company focused on developing individualized cell therapies targeting solid tumors. | Diakonos Oncology Corporation is looking for individuals/teams with expertise in assay development, bioinformatics, and manufacturing automation. | TA1: Automated RNA Manufacturing |
| Yonas Tadesse | UT Dallas | yonas.tadesse@utdallas.edu | Richardson, TX | Automated manufacturing integrates robotics, AI, and smart materials to enable precision, scalability, and adaptability in production systems. My work focuses on soft robotic actuators, intelligent sensing, additive and 4D printing, and AI-driven design optimization—technologies that align closely with Automated RNA Manufacturing for developing adaptive and automated systems. I Have published over 130 papers and filed 15 patents, and I am looking for problems to solve and partner. | The HBS Lab at the University of Texas at Dallas conducts research in advanced manufacturing, smart materials, robotic systems, and machine learning/artificial intelligence. Our work focuses on developing innovative technologies that integrate intelligent systems with adaptive materials for next-generation automation and computer aided design | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Scott Stankey | Bramante Biologics Corporation | scott@bramantebio.com | Cambridge, MA | Bramante Biologics builds AI-native, modular GMP microfactories to translate sequences into scalable therapeutics. Our R&D spans autonomous bioprocessing (real-time PAT, digital twins, closed-loop control), rapid tech transfer, in-line QC, and containerized, rapidly deployable production. | We are interested in speaking to equipment OEMs, PAT/AI software providers, GMP/CDMO sites, and CMC/regulatory experts | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Michal Karlubik | Sensible Biotechnologies Inc. | michal@sensible.bio | Oxford, United Kingdom; Bratislava, Slovakia; Boston, US, MA | Sensible Biotechnologies has developed the world’s first cell-based mRNA manufacturing platform producing RNA of unparalleled purity - free from dsRNA impurities, with minimal immunogenicity and strong protein expression. Our PROMPT™-powered mRNA production technology eliminates reliance on costly, fragile IVT inputs & raw materials, enabling scalable, resilient, and affordable mRNA production optimized for human medicines. | We seek partners who share our mission to unlock mRNA therapeutics through next-generation manufacturing. Ideal collaborators contribute complementary strengths in automation, analytics, delivery or clinical validation - particularly U.S.-based teams that can help integrate, scale, and demonstrate our resilient, cell-based mRNA platform within ARPA-H GIVE’s decentralized production vision. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Brent Dixon | Carolina BioOncology Institute, PLLC (CBOI) | BDIXON@carolinabiooncology.org | Huntersville, NC | Carolina BioOncology Institute, PLLC (CBOI) is a Phase 1 Clinical Trials research center founded in 2005. We focus on providing patients with individualized clinical trial options. These include RNA based genetic medicines for solid tumor cancer patients. | Creative and innovative RNA developers and device manufacturers seeking an integrated phase 1 study site with decentralized point-of-care (PoC) manufacturing GMP capabilities. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Avanish Mishra | MGH, Harvard Medical School | amishra2@mgh.harvard.edu | Boston, MA | Our research focus is on integrated cell therapy manufacturing on a chip technology. We are developing a platform technology that can perform all steps of RNA-based cell therapy manufacturing, including cell sorting, poration, incubation, and washing, entirely within a single compact device. | We are looking for partners in integrated quality control | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| David Alburty | InnovaPrep | dalburty@innovaprep.com | Drexel, MO | Sample prep and QA/QC, dosing with simultaneous quality control and endotoxin reduction, automated concentration and matrix/buffer exchange | We can help integrate our sample prep solutions into full-stack solutions/systems | TA2: Integrated Quality Control |
| Prasun Chakraborty | GenevationUS | prasun.chakraborty@genevationus.com | London | Personalized Cancer Vaccines, RNA vaccine platform, AI in Healthcare, End-to-End vaccine manufacturing | We seek partners with complementary expertise in RNA synthesis, formulation, and analytical characterization to enhance scalability, quality, and automation of RNA manufacturing. Ideal collaborators offer innovative process engineering, automation technologies, regulatory experience, and strong track records in translational RNA therapeutics development to accelerate ARPA-H goals. | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Kris Ward | Landmark Bio | kward@landmarkbio.com | Watertown, MA, MA | Technology integration and GMP infrastructure to support manufacturing and release. Our team has significant commercialization expertise to lend to platform development efforts as well to ensure the platform aims to address not just manufacturing and analytics for Phase 1, but for later phase clinical and commercialization as well. | Therapeutic partners with an advanced clinical candidate. DNA template solutions partner. Automation and manufacturing systems engineering partner. Integrated QC and PAT analytics partner. Analytical instrumentation and assay development partner. Digital twin//predictive modeling partner | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Dean Bornilla | Pace Life Sciences | dean.bornilla@pacelabs.com | Woburn, MA | Pace has extensive capabilities in formulation, analytical, and process development, characterization, as well as GMP manufacturing and testing for genetic RNA based medicines. Pace provides FDA regulatory, GxP consulting, and facility and cleanroom inspection support | Seeking collaborators with technical expertise in equipment development | TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control |
| Neeraj Salathia | Cellanome | neeraj.salathia@cellanome.com | San Diego, CA | Cellanome’s multimodal platform integrates live cell incubation with imaging, proteomic, and RNA profiling capabilities. The system enables tracking of cellular phenotypes across thousands of cells with single cell resolution. By linking molecular measurements to functional outcomes, the platform addresses a critical gap in RNA therapeutic development: the ability to simultaneously assess quality control metrics and functional performance for RNA modalities in physiologically relevant contexts. | The platform supports therapeutic characterization across preclinical and manufacturing workflows. Researchers can screen thousands of guide RNA constructs, capturing knockdown efficiency, imaging, protein and transcriptional data. For drug delivery optimization, single cell measurements can link stable non-immunogenic constructs to cellular response. Quality control applications include full-length RNA integration profiling, temporally connecting multimodal data with therapeutic potency. | TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing |
| Matthew Hewitt | Charles River Laboratories | matthew.hewitt@crl.com | Rockville, MD | We are full service end-to-end CRO/CDMO with significant experience in preclinical development, manufacturing, and testing across all therapeutic modalities but do have extensive experience in RNA and other nucleic acid therapies. | Opportunities to work across the industry to bring new therapeutics to market. | TA2: Integrated Quality Control, TA2: Integrated Quality Control |